News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel

News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel
Sign In

Higher Enrollment in Medicare Advantage Plans Means that More Local Clinical Laboratories and Pathology Groups Lose Access to these Patients

Health insurers offering Medicare Advantage plans are narrowing their networks and favoring the national clinical lab companies over local medical labs and pathology groups

Enrollment in Medicare Advantage health plans is booming. This development is not auspicious for local medical laboratories, hospital lab outreach programs, and anatomic pathology groups because the private health insurers operating these plans typically prefer to contract with national lab companies while narrowing their lab networks.

The mathematics of this trend are simple. As Medicare Advantage enrollment increases, the proportion of patients covered by traditional Medicare Part B fee-for-service shrinks. The consequence is that local labs have fewer Medicare Part B patients to serve and are locked out of providing medical laboratory testing services to Medicare Advantage patients. (more…)

CLMA Is Launching New Program to Help Clinical Laboratories Develop Patient-Centric Services and Deliver More Value to ACOs and Medical Homes

To help medical laboratories understand how to deliver patient-centric lab testing services, the Clinical Laboratory Management Association (CLMA) has launched its “Increasing Clinical Effectiveness” (ICE) program. CLMA President Paul Epner (pictured above) will be conducting a free webinar about the ICE program on August 12 and the details of ICE and the webinar can be found at the CLMA website. (Photo copyright CLMA.)

Increasing Clinical Effectiveness’ is the name of new initiative that CLMA is making available to all medical laboratories and anatomic pathology groups

There is now little disagreement that the U.S. healthcare system is in the midst of a transformation away from reactive and acute care and to proactive, integrated clinical care. This is why clinical laboratories and anatomic pathology groups across the nation now find themselves at a critical crossroads.

This trend presents medical laboratory managers, pathologists, and clinical chemists who lead the nation’s labs with an important question: When is it time to shift the lab’s focus away from its traditional “lab-centric” emphasis and position the lab as a “patient-centric” clinical service?
(more…)

CVS MinuteClinic to Use Epic EMR in Support of Nationwide Growth Plan, also Opens Possibility of Accessing Clinical Laboratory Data from Local Providers

It’s an interesting statement about how CVS, the national pharmacy chain, believes it can expand its MinuteClinic health services while also integrating data feeds with HIEs

In another demonstration of how fast healthcare is transforming, the pharmacy chain CVS Caremark Corp. will implement the Epic electronic medical record system (EMR) in its MinuteClinic sites nationwide. This means MinuteClinic clinicians will be using the same EMR as a growing number of hospitals and office-based physicians.

What may make this development noteworthy for pathologists and clinical laboratory managers is that use of the EpicCare EMR system sold by Epic Systems Corp. of Verona, Wisconsin, is that MinuteClinic sites will make it easier for CVS to pass clinical data it gathers to regional health information exchanges (HIEs). (more…)

Some Hospital-based Physician Pay Trends Identified by Becker’s Hospital Review Could Play to Pathology’s ‘Sweet Spot’

Savvy pathologists and clinical laboratory professionals will look for ways to generate increased value to clinicians by becoming partners and consultants in clinical decisions

Becker’s Hospital Review has identified seven trends in hospital-based physician pay that have emerged over the past several years. These trends reflect fundamental changes in the private practice of medicine and will be of interest to those pathologists and clinical laboratory managers who provide medical laboratory tests to office-based physicians.

As defined by Becker’s in a story published last year, the seven trends indicate shifts in income, along with increasing numbers of physicians migrating out of private practice to salaried hospital positions. Pathologists will want to keep these trends in mind as they plan their personal careers, taking special note of emerging opportunities to generate value in new ways. (more…)

Congress Passes Law Changing How Medicare Sets Prices for Clinical Laboratory Tests; Lab Industry Groups Differ on Which Labs Will Be Winners and Losers

Leaders from ACLA, AdvaMedDx, CAP, NILA will be at Executive War College on April 29-30 for first medical lab industry debate about the best and worst of the new law

Clinical laboratories will face new financial challenges following passage of a new federal law two weeks ago that makes deep changes in the way Medicare officials will establish prices for the Medicare Part B Clinical Laboratory Fee Schedule (CLFS). Many medical laboratory administrators, hospital lab managers, and pathologists remain unaware of the significant negative financial impact this law will have on their lab’s revenue and fiscal stability.

On April 1, President Barack Obama signed H.R. 4302: Protecting Access to Medicare Act of 2014. The law’s primary purpose is to extend the Sustainable Growth Rate (SGR) formula for 12 months. The House had passed the bill on the previous Thursday and the Senate passed the bill on the following Monday, March 31. (more…)

Facing the Looming End of Fee-for-Service, Clinical Laboratories and Anatomic Pathology Groups Look for New Business Models

Failing finances at technical pathology laboratories may be the most immediate concern for many pathology group practices

Many clinical laboratories and anatomic pathology groups now recognize the new reality of the American healthcare system: less reimbursement for laboratory testing. On one hand, the fee-for-service prices for lab tests paid by government and private payers have been aggressively slashed.

On the other hand, all payers have become stubbornly resistant to issuing coverage guidelines and setting adequate prices for the flood of new molecular assays and gene tests coming to market.

These trends have already brought a handful of medical laboratories and pathology practices to the point of bankruptcy, sale, or closure. This is definitely true for the technical laboratories owned by many local pathology groups, which have become unprofitable due to fee cuts. (See below.) (more…)

;